Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $1.1 million.

  • Gyre Therapeutics' Share-based Compensation rose 38396.62% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 5625.35%. This contributed to the annual value of $831000.0 for FY2024, which is 8858.67% down from last year.
  • Gyre Therapeutics' Share-based Compensation amounted to $1.1 million in Q3 2025, which was up 38396.62% from $906000.0 recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Share-based Compensation peaked at $12.3 million during Q4 2022, and registered a low of $11000.0 during Q1 2024.
  • For the 5-year period, Gyre Therapeutics' Share-based Compensation averaged around $1.4 million, with its median value being $515000.0 (2022).
  • As far as peak fluctuations go, Gyre Therapeutics' Share-based Compensation plummeted by 9476.19% in 2024, and later soared by 556250.0% in 2025.
  • Over the past 5 years, Gyre Therapeutics' Share-based Compensation (Quarter) stood at $683000.0 in 2021, then skyrocketed by 1698.1% to $12.3 million in 2022, then tumbled by 43.95% to $6.9 million in 2023, then tumbled by 91.76% to $567000.0 in 2024, then skyrocketed by 102.29% to $1.1 million in 2025.
  • Its Share-based Compensation was $1.1 million in Q3 2025, compared to $906000.0 in Q2 2025 and $507000.0 in Q1 2025.